Simponi Works for Patients with AS, RA, and PsA – Even with Prior TNF Inhibitor Treatment
mohamed_hassan / Pixabay

Simponi Works for Patients with AS, RA, and PsA – Even with Prior TNF Inhibitor Treatment

  In some cases, people have a medical condition that doesn't respond well to treatments. The journey to finding an effective treatment can be long and difficult. But for patients…

Continue Reading Simponi Works for Patients with AS, RA, and PsA – Even with Prior TNF Inhibitor Treatment

A Subcutaneous Form of Remsima May be Available Soon in the EU

Celltrion Healthcare has just announced positive progress for extending the authorization for the subcutaneous (SC) form of Remsima to five more autoimmune conditions. These are- Psoriatic arthritis Ankylosing spondylitis (AS)…

Continue Reading A Subcutaneous Form of Remsima May be Available Soon in the EU

New Lifestyle Guidelines Will Improve QOL for Patients with Rheumatic and Musculoskeletal Diseases (RMDs)

At this year's EULAR 2020 E-Congress, Dr. Suzanne Verstappen, MD, presented on how lifestyle changes could benefit patients with rheumatic and musculoskeletal diseases (RMDs). Her interest in the impact of…

Continue Reading New Lifestyle Guidelines Will Improve QOL for Patients with Rheumatic and Musculoskeletal Diseases (RMDs)

Sixty Year Old Multiple Myeloma Patient in Wuhan, China Treated Successfully with Tocilizumab for COVID-19

  Dr. Changcheng Zheng of the University of Science, China, recently spoke to Cancer Network about a case study indicating that tocilizumab (Actemra) could effectively treat people with multiple myeloma…

Continue Reading Sixty Year Old Multiple Myeloma Patient in Wuhan, China Treated Successfully with Tocilizumab for COVID-19
Controls Needed for the Dupuytren Biomarker Discovery Pilot Study
source: pixabay.com

Controls Needed for the Dupuytren Biomarker Discovery Pilot Study

We need controls! No, not cockpit controls or videogame controls, and no, we're not out of control. We need control participants for the Dupuytren Biomarker Discovery Pilot Study. Our goal is…

Continue Reading Controls Needed for the Dupuytren Biomarker Discovery Pilot Study
Study: Felty’s Syndrome Presents Differently in Pediatric Patients
source: pixabay.com

Study: Felty’s Syndrome Presents Differently in Pediatric Patients

According to a study published in BMC Pediatrics, the rare disease known as Felty's syndrome is primarily known to affects adults between the ages of 50 and 70, but on very rare…

Continue Reading Study: Felty’s Syndrome Presents Differently in Pediatric Patients

Immunocompromised During COVID-19? Not Much Has Changed in the Lives of Many Rare Patients

Relapsing polychondritis is a rare disease which causes damage to the cartilage, trachea, and lungs. It's an autoimmune condition meaning an overzealous immune response causes the body to attack its own…

Continue Reading Immunocompromised During COVID-19? Not Much Has Changed in the Lives of Many Rare Patients
A Simple Blood Test Could Lead to Personalized Therapies for Rheumatoid Arthritis and Related Diseases
source: pixabay.com

A Simple Blood Test Could Lead to Personalized Therapies for Rheumatoid Arthritis and Related Diseases

A recent study led by Morten Aagaard Nielsen and Tue Wenzel Kragstrup, who both work at Aarhus University in Denmark, hopes to help physicians determine the best personalized treatment for…

Continue Reading A Simple Blood Test Could Lead to Personalized Therapies for Rheumatoid Arthritis and Related Diseases
A Biosimilar Drug for Treating Rheumatoid Arthritis and Ankylosing Spondylitis Begins Phase 3 Trials
source: pixabay.com

A Biosimilar Drug for Treating Rheumatoid Arthritis and Ankylosing Spondylitis Begins Phase 3 Trials

According to a story from Acrofan, the biotechnology company Clover Pharmaceuticals Inc. has recently announced that the first patient has been dosed in its phase 3 clinical study. This study…

Continue Reading A Biosimilar Drug for Treating Rheumatoid Arthritis and Ankylosing Spondylitis Begins Phase 3 Trials

A Blind Artist, A Motivational Speaker Who Can’t Talk, and a Single Mom with Rheumatoid Arthritis

  Since most people cannot truly understand the challenges faced by a blind person, then an artist who cannot see is unimaginable. According to a recent article in the British…

Continue Reading A Blind Artist, A Motivational Speaker Who Can’t Talk, and a Single Mom with Rheumatoid Arthritis

Legal and Ethical Questions: What is Pharma’s Obligation to Pursue Development of a Promising but Non-Profitable Drug?

  Dr. Craig Klugman, a bioethics professor at DePaul University, expresses his opinion in this recent article in Columbia University’s Bioethics.com. Dr. Klugman begins with a discussion of Pfizer’s biological drug,…

Continue Reading Legal and Ethical Questions: What is Pharma’s Obligation to Pursue Development of a Promising but Non-Profitable Drug?

The FDA is Reversing Course on Unapproved Products Sold by Stem Cell Manufacturers

  The FDA’s “untitled letter” to R3 Stem Cell (R3), based in Scottsdale Arizona, cautioned R3 that the product they are marketing is considered a drug. It must, therefore, be…

Continue Reading The FDA is Reversing Course on Unapproved Products Sold by Stem Cell Manufacturers